



## LETTER OPEN

## Visual function restoration with a highly sensitive and fast Channelrhodopsin in blind mice

Signal Transduction and Targeted Therapy (2022)7:104

; <https://doi.org/10.1038/s41392-022-00935-x>

## Dear Editor,

Inherited and age-related retinal degenerative diseases cause progressive loss of photoreceptors, ultimately leading to blindness. Optogenetics is a promising strategy for restoring visual function through photosensitive proteins' ectopic expression in surviving retinal neurons.<sup>1</sup> Very recently, the optogenetic method with a red-shifted Channelrhodopsin was clinically applied for partial recovery of visual function in a blind patient.<sup>2</sup> However, major obstacles to achieving optimal optogenetic vision restoration are either the low light sensitivity or the slow kinetics of existing rhodopsin-based optogenetic tools, which can be improved by molecular engineering to enhance the efficacy of fast Channelrhodopsins (ChRs). Here, we present a newly engineered ChR variant *PsCatCh2.0*, engineered from *PsChR*,<sup>3</sup> which displays inherently high  $\text{Ca}^{2+}$  and  $\text{Na}^{+}$  conductance and fast kinetics.<sup>3,4</sup> We introduced a novel mutation *PsChR* L115C (*PsCatCh*) to enhance its  $\text{Ca}^{2+}$  and  $\text{Na}^{+}$  permeability further and fused the cleavable N-terminal signal peptide Lucy-Rho (LR<sup>5</sup> in Fig. 1a), in addition to a plasma membrane trafficking signal (T) and ER export signal (E), to improve its expression and plasma membrane targeting. *PsCatCh2.0* exhibited significant improvements in expression levels/plasma membrane targeting efficiency and a larger photocurrent (Fig. 1a, b, e). 100-fold less light intensity is needed to generate a similar photocurrent response with *PsCatCh2.0* than with *CatCh* (Fig. 1b), with BAPTA,  $\text{Ca}^{2+}$  currents of *PsCatCh2.0* were four times larger than those generated by *CatCh* (Fig. 1c, d), indicating that *PsCatCh2.0* is a highly effective excitatory tool for future clinical applications.

The photosensitivity and kinetics of *PsCatCh2.0* were further investigated *in vivo* in rd1 mice. Notably, a low light intensity ( $3.7 \times 10^{14}$  photons/cm<sup>2</sup> s) evoked a 14.5 pA ( $14.5 \pm 7.4$ ,  $n = 5$ ) current in *PsCatCh2.0*-expressing RGCs in rd1 mice (Fig. 1g). It also presented a persistent periodic response that could follow up to 32 Hz light stimuli, without obvious desensitization (Fig. 1h), clearly outperformed MCO1 in kinetic aspect.<sup>6</sup> Moreover, *PsCatCh2.0* could reliably induce action potentials firing at 100 Hz when expressing in the hippocampal neuron (Supplementary Fig. 1). We tested whether visual information input could be transmitted from the *PsCatCh2.0*-treated retina to the brain in rd1 mice. We assessed the activity in the V1 cortex induced by light through c-Fos and Arc. Following 2 h of continuous light stimulation (470 nm,  $4.7 \times 10^{14}$  photons/cm<sup>2</sup> s), both IEGs c-Fos (red) and Arc (green) were expressed in the light-stimulated retina and V1 cortex of wild-type and *PsCatCh2.0*-expressing rd1 mice (Fig. 1j, k, m–o). In contrast, rd1 mice retina exhibited neither obvious light responses nor upregulation of IEGs in the visual cortex. Additionally, blue light flash visual evoked potential (VEP) recording in the visual cortex was performed. No obvious N1 amplitude in rd1 mice was recorded ( $1.6 \pm 1.0$   $\mu\text{V}$ ,  $n = 8$ ) compared to the wild-type mice ( $-24.7 \pm 6.7$   $\mu\text{V}$ ,  $n = 8$ , Fig. 1i, l). In *PsCatCh2.0*-treated rd1 mice, the N1 amplitude of VEP was

restored to  $-12.4$   $\mu\text{V}$  ( $-12.4 \pm 1.8$   $\mu\text{V}$ ,  $n = 8$ ), suggesting regained visual function after optogenetic treatment of blind mice.

Finally, we evaluated visually guided behavior in *PsCatCh2.0*-treated rd1 mice. The fraction of time spent in light boxes, the distance and speed of movement for discovering the hole to the dark box were recorded. *PsCatCh2.0*-treated rd1 mice in the blue-light chamber could easily find the hole entering to the dark box, with similar performance as the wild-type mice (percentage of time spent in the light box: *PsCatCh2.0*,  $40.8\% \pm 3.7$  ( $n = 19$ ); wild-type,  $40.1\% \pm 2.1$  ( $n = 11$ ); rd1,  $86.1\% \pm 4.0$ , ( $n = 13$ ); one-way ANOVA; Fig. 1q). *PsCatCh2.0* also rescued the distance and average speed performance of rd1 mice to the wild-type level (Fig. 1r: distance (cm): wild-type,  $101.9 \pm 25.7$ ,  $n = 11$ ; *PsCatCh2.0*,  $82.3 \pm 22.5$ ,  $n = 19$ ; rd1,  $1058 \pm 108.3$ ,  $n = 13$ ; Fig. 1s: average speed (cm/s): *PsCatCh2.0*,  $7.7 \pm 0.6$ ,  $n = 19$ ; wild-type,  $7.6 \pm 1.3$ ,  $n = 11$ ; rd1,  $4.8 \pm 0.5$ ,  $n = 13$ ). Especially, *PsCatCh2.0*-treated rd1 mice showed visual tracking behavior to the grating flash with an average peak spatial frequency of  $0.22 \pm 0.02$  (c/d), compared to no response of the rd1 littermates, and  $0.53 \pm 0.02$  c/d of the wild-type mice (Fig. 1t). Therefore, *PsCatCh2.0*-treated rd1 mice improved visual acuity dramatically.

A light intensity of  $4.7 \times 10^{14}$  photons/cm<sup>2</sup> s was all present to induce retinal, cortical and behavioral responses, which is safe for light therapy. In this study, *PsCatCh2.0* was expressed in retinal ganglion cells of blind rd1 mice. Visual acuity raised to 0.22 c/d, with a temporal resolution of at least 32 Hz. The faster and larger current *PsCatCh2.0* may be an optimal therapeutic option for the treatment of retinal degeneration. Furthermore, the blue-shifted action spectrum of *PsCatCh2.0* (Supplementary Fig. 2) provided the possibility to combine with red-shifted optogenetic tools<sup>2</sup> to achieve colored vision restoration in the future.

## DATA AVAILABILITY

The data sets used for the current study are available from the corresponding author upon reasonable request.

## ACKNOWLEDGEMENTS


This work was supported by National Key R&D Program of China (2017YFE0103400) to Y.S., National Nature Science Foundation of China (81900874) to Y.C., Macao Science and Technology Development Fund to Kang Zhang (0007/2020/AFJ) and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Projektnummer 374031971 TRR 240 A04 and DFG Projektnummer 417451587 to G.N.

## AUTHOR CONTRIBUTIONS

G.N., S.G., and Y.S. conceived the project, designed the experiments. X.D., S.Y., and C.E.G. conducted the experiments that genetically engineered a new ChR, *PsCatCh2.0*, and verified its molecular characteristics. F.C. and Y.Y. conducted the experiments that used this optogenetic tool to detect the effect of visual restoration in rd1 mice. G.N., S.G., Y.S., and K.Z. wrote and revised the paper.

Received: 20 July 2021 Revised: 8 February 2022 Accepted: 18 February 2022

Published online: 18 April 2022



**Fig. 1** The characterizations of PsCatCh2.0, and the efficiency for vision restoration by optogenetics in rd1 mice. **a** Scheme of PsCatCh2.0 and representative photocurrent traces of CatCh and PsCatCh2.0 measured by two-electrode voltage clamp (TEVC) in *Xenopus* oocyte. **b** Stationary photocurrents of CatCh, PsCatCh and PsCatCh2.0 illuminated by different intensities of blue (450 nm) light.  $n = 3$ . **c** Representative photocurrent traces of CatCh and PsCatCh2.0 in 80 mM CaCl<sub>2</sub> pH 9.0 buffer with (both top traces) and without 10 mM BAPTA injection, holding at  $-100$  mV. **d** Comparison of the CatCh and PsCatCh2.0 calcium current.  $n = 6-7$ . **e** Fluorescence pictures (left) of PsCatCh and PsCatCh2.0-expressing oocytes and fluorescence emission values (right) of PsCatCh and PsCatCh2.0-expression oocytes. All measurements were done two days after injecting 20 ng cRNA into fresh oocytes.  $n = 4$ . **f** Representative image of whole-cell patch-clamp recording ganglion cell in PsCatCh2.0-treated rd1 retinal slice, the light-evoked current traces of PsCatCh2.0-expressed RGCs with 1 s light pulses at 470 nm under different light intensities measured as photons/cm<sup>2</sup> s. **g** The light intensity and current response relationship were measured at peak and plateau currents.  $n = 5$ . **h** Temporal properties of PsCatCh2.0 in retina induced photocurrents at increasing stimulation frequencies at a light intensity of  $2.7 \times 10^{16}$  photons/cm<sup>2</sup> s of 470 nm blue light. **i** Representative VEP waveforms. **j** Representative co-labeling of c-Fos (red), an immediate early gene, with GFP (green) in vertical retinal sections. **k** Representative co-labeling of light-induced immediate early genes c-Fos (red) and Arc (green) in the V1 area of the visual cortex. **l** Graphed VEP N1 amplitudes.  $n = 8$ . Representative result of counting positive cells of c-Fos or Arc in the retina (**m**) and V1-visual cortex (**n**, **o**), respectively. All mice experiments under the light intensity of  $4.7 \times 10^{14}$  photons/cm<sup>2</sup> s of 470 nm blue light. One-way ANOVA test,  $^{**}P < 0.01$ ,  $^{***}P < 0.001$ . Scale bars, 20  $\mu$ m (**j**, **k**).  $n = 5$ . **p** Representative traces of the first time to find the hole in light/dark box. **q** Percentage of time spent in the light compartment under a light intensity of  $4.7 \times 10^{14}$  photons/cm<sup>2</sup> s.  $n = 11-19$ . **r**, **d** Representative distance and average velocity of the first time to find the hole in light/dark box, one-way ANOVA test,  $^{***}P < 0.001$ . **t** The average spatial acuity of mice (t-test,  $^{***}P < 0.001$ ). Stimulus light intensity  $4.7 \times 10^{14}$  photons/cm<sup>2</sup> s. All data showed mean  $\pm$  SD

## ADDITIONAL INFORMATION

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41392-022-00935-x>.

**Competing interests:** The authors declare no competing interests. Kang Zhang is one of the Editors-in-Chief of Signal Transduction and Targeted Therapy, but he has not been involved in the process of the manuscript handling.

Fei Chen<sup>1</sup>, Xiaodong Duan<sup>2</sup>, Yao Yu<sup>1</sup>, Shang Yang<sup>2</sup>, Yuanyuan Chen<sup>1</sup>, Christine E. Gee<sup>3</sup>, Georg Nagel<sup>2</sup>, Kang Zhang<sup>4,5</sup>, Shiqiang Gao<sup>2,6</sup> and Yin Shen<sup>1,5</sup>

<sup>1</sup>Eye Center, Wuhan University Renmin Hospital, Wuhan, China; <sup>2</sup>Department of Neurophysiology, Institute of Physiology, Biocenter, University of Wuerzburg, Wuerzburg, Germany; <sup>3</sup>Institute for Synaptic Physiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany; <sup>4</sup>Center for Biomedicine and Innovations, Faculty of Medicine, Macau University of Science and Technology and University Hospital, Macau, China and <sup>5</sup>Frontier Science Center for Immunology and Metabolism, and Medical Research Institute at School of Medicine, Wuhan University, Wuhan, China

These authors contributed equally: Fei Chen, Xiao-dong Duan, Yao Yu

Correspondence: Kang Zhang ([kang.zhang@gmail.com](mailto:kang.zhang@gmail.com)) or Shiqiang Gao ([gao.shiqiang@uni-wuerzburg.de](mailto:gao.shiqiang@uni-wuerzburg.de)) or Yin Shen ([yinshen@whu.edu.cn](mailto:yinshen@whu.edu.cn))

## REFERENCES

- Gauvain, G. et al. Optogenetic therapy: high spatiotemporal resolution and pattern discrimination compatible with vision restoration in non-human primates. *Commun. Biol.* **4**, 125 (2021).
- Sahel, J. A. et al. Partial recovery of visual function in a blind patient after optogenetic therapy. *Nat. Med.* **27**, 1223–1229 (2021).
- Govorunova, E. G. et al. Characterization of a highly efficient blue-shifted Channelrhodopsin from the marine alga *Platymonas subcordiformis*. *J. Biol. Chem.* **288**, 29911–29922 (2013).
- Duan, X., Nagel, G. & Gao, S. Mutated Channelrhodopsins with increased sodium and calcium permeability. *Appl. Sci.—Basel.* **9**, 664 (2019).
- Zhou, Y. et al. Optogenetic control of plant growth by a microbial rhodopsin. *Nat. Plants* **7**, 144–151 (2021).
- Batabyal, S. et al. Sensitization of ON-bipolar cells with ambient light activatable multi-characteristic opsin rescues vision in mice. *Gene Ther.* **28**, 162–176 (2021).



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022